Patient Advocate Foundation Announces New Funding for Patients available through its Co-Pay Relief Program

Tuesday, October 14, 2014

HAMPTON, VA   - Patient Advocate Foundation (PAF) is pleased to announce the availability of robust new funding for insured patients who are in need of financial assistance with their pharmaceutical co-payments made possible through multiple donations.  The new funding will allow PAF’s Co-Pay Relief (CPR) program to expand its support of patients suffering with Breast Cancer, Cervical Cancer, Hepatitis C, Multiple Myeloma or Myelodysplastic Syndromes.

CPR provides insured patients with direct financial support for co-payments, co-insurance and deductibles associated with pharmaceutical treatments and/or prescription medications prescribed to treat and/or manage their disease.  PAF is a leader in the field of financial support programs.  Launched in 2004 -- the second of its kind nationally --   the CPR program at PAF has provided over $200 million in financial assistance to more than 126,000 patients, many of whom would have otherwise been unable to afford their pharmaceutical co-payments. In FY2013-2014 alone, PAF’s program assisted 20,835 patients, fielded 121,460 patient calls that lead to more than $32 million in direct patient support.

“PAF’s Co-Pay Relief Program was created a decade ago in response to the growing financial needs reported to our case managers by patients reaching out to Patient Advocate Foundation as they struggled to manage the costs associated with the treatment of critical and chronic health conditions.  We are committed to helping people, one at a time, who need access to life-changing therapies at one of the most critical times in their treatment journey.” said Alan Balch, CEO of PAF. “Today, financial struggles continue for many patients with chronic and life-threatening illness and the availability of these funds will have an enormous impact in patients’ lives by alleviating some of the financial burden.”

As a result of these donations, PAF’s Co-Pay Relief program will be able to expand its co-payment support to patients battling Breast Cancer, Cervical Cancer, Hepatitis C, Multiple Myeloma, or Myelodysplastic Syndromes and who are facing significant financial hardship